Valuation: Xspray Pharma AB

Market Cap 651M 68.12M 59.02M 55.48M 50.47M 94.83M 6.5B 96.41M 254M 3.26B 256M 250M 10.94B P/E 2026 *
-2.21x
P/E 2027 * 4.16x
Enterprise Value 651M 68.12M 59.02M 55.48M 50.47M 94.83M 6.5B 96.41M 254M 3.26B 256M 250M 10.94B EV / Sales 2026 *
33.7x
EV / Sales 2027 * 1.15x
Free-Float
75.05%
Yield 2026 *
-
Yield 2027 * -
1 day+0.15%
1 week-11.14%
Current month-18.72%
1 month-8.17%
3 months-43.54%
6 months-45.56%
Current year-56.38%
1 week 13.4
Extreme 13.4
15.4
1 month 13.4
Extreme 13.4
17.24
Current year 13.4
Extreme 13.4
32.5
1 year 13.4
Extreme 13.4
64.1
3 years 13.4
Extreme 13.4
91.7
5 years 13.4
Extreme 13.4
147.2
10 years 13.4
Extreme 13.4
267
Manager TitleAgeSince
Chief Executive Officer - 2026-05-31
Director of Finance/CFO 34 -
Chief Tech/Sci/R&D Officer 73 2022-12-31
Director TitleAgeSince
Director/Board Member 70 2014-12-31
Director/Board Member 52 2018-12-31
Chairman 72 2022-05-18
Date Insider Type Main position Quantity % Market Cap.
4/22/26 Buy

Director

810 0.0019%
4/22/26 Sell

Director

4 0.0000%
9/19/25 Buy

Director

2,063 -
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%-11.14%-73.31%-57.12% 68.04M
+2.07%+10.05%+77.41%+106.53% 70.1B
-0.87%+0.77%+36.57%+65.91% 54.93B
-4.50%+27.58%+3.55%+463.22% 28.89B
+0.04%+12.56%+54.67%+5.47% 23.9B
-0.67%-0.07%-17.01%-13.84% 23.3B
+0.35%+8.24%+252.94%+466.50% 18.41B
-0.59%+7.03%+46.32%-20.56% 18.77B
-0.57%+6.85%+30.20%+580.70% 16.1B
+0.46%-10.74%+33.36%+135.18% 12.48B
Average -0.41%+6.24%+44.47%+173.20% 26.69B
Weighted average by Cap. -0.21%+8.03%+55.71%+162.99%

Financials

2026 *2027 *
Net sales 19.3M 2.02M 1.75M 1.65M 1.5M 2.81M 193M 2.86M 7.54M 96.63M 7.59M 7.42M 324M 564M 59.05M 51.17M 48.1M 43.75M 82.21M 5.63B 83.58M 220M 2.82B 222M 217M 9.48B
Net income - -
Net Debt - -
Logo Xspray Pharma AB
XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.
Employees
24
Date Price Change Volume
26-08-13 SEK 13.72 +0.15% 56,162
26-08-12 SEK 13.70 -0.72% 56,364
26-08-11 SEK 13.80 -3.77% 132,818
26-08-10 SEK 14.34 -4.53% 133,638
26-08-07 SEK 15.02 +2.04% 103,473

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XSPRAY Stock